CANTOS Trial Brings Unexpected CVD Promise For Novartis & Regeneron
Few expected the positive top-line results from CANTOS showing the Phase III cardiovascular disease study using canakinumab met the primary endpoint. Most want to see the full details being unveiled later in 2017.
You may also be interested in...
'Study 4' results may support a label claim related to reducing inflammation – measured through the high sensitivity C-reactive protein (hsCRP) marker – down the line, the company told investors.
Scrip takes a trip back through the highs of drug development, looking at successes including positive cardiovascular outcomes studies for cholesterol drugs, advances in cancer and breakthroughs in hemophilia.
What caused Novartis's innovative heart failure drug to falter, missing sales targets by $30m in 2016, and how is it expected to bounce back in 2017? Scrip explores Entresto's journey and what this experience shows about the changing face of pharma's customers.